PFA Pension Forsikringsaktieselskab Purchases New Holdings in Gilead Sciences, Inc. $GILD

PFA Pension Forsikringsaktieselskab purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 826,930 shares of the biopharmaceutical company’s stock, valued at approximately $101,861,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Ares Financial Consulting LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at about $28,000. Corundum Trust Company INC acquired a new stake in Gilead Sciences in the 3rd quarter valued at about $26,000. Financial Consulate Inc. raised its holdings in Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 109 shares during the last quarter. North Star Investment Management Corp. raised its holdings in Gilead Sciences by 54.8% in the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 86 shares during the last quarter. Finally, BOCHK Asset Management Ltd acquired a new stake in Gilead Sciences in the 4th quarter valued at about $31,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Up 0.6%

Shares of NASDAQ GILD opened at $131.65 on Friday. The company has a 50 day simple moving average of $140.49 and a 200-day simple moving average of $132.35. The company has a market capitalization of $163.41 billion, a P/E ratio of 19.45, a P/E/G ratio of 1.73 and a beta of 0.39. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. Gilead Sciences, Inc. has a 1 year low of $95.29 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business’s revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post 8.62 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were issued a dividend of $0.82 per share. The ex-dividend date was Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is 48.45%.

Wall Street Analyst Weigh In

A number of analysts have commented on GILD shares. Daiwa Securities Group increased their price objective on shares of Gilead Sciences from $129.00 to $161.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Leerink Partners increased their price objective on shares of Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Finally, Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, February 11th. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $157.35.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: FDA gives priority review to Gilead’s once‑daily bictegravir + lenacapavir HIV regimen, shortening the path to U.S. commercialization if approved — a clear revenue and de‑risking catalyst. Read More.
• Positive Sentiment: Gilead completed the Arcellx acquisition (~$7.8B), adding the anito‑cel cell therapy to its oncology pipeline and boosting longer‑term growth optionality beyond antivirals. Read More.
• Positive Sentiment: Analyst bullishness: Morgan Stanley and other shops have raised price targets/ratings recently, signaling analyst support that can attract buyers. Read More.
• Neutral Sentiment: Gilead scheduled presentations at several investor conferences (BofA, RBC, Bernstein, Goldman Sachs) — increases visibility and provides opportunities to update guidance/portfolio progress but is informational rather than a direct catalyst. Read More.
• Neutral Sentiment: Pre‑earnings coverage highlights HIV franchise strength versus cell‑therapy cost/headwinds; Wall Street expects modest earnings growth into the next print — sets expectations for the upcoming report. Read More.
• Negative Sentiment: CEO Daniel O’Day sold shares under a Rule 10b5‑1 plan (recent transactions disclosed), which can create short‑term headline pressure even if planned. Read More.
• Negative Sentiment: Advocacy group AHF filed a shareholder resolution seeking more transparency on patent exclusivities — raises governance/IP scrutiny that could produce regulatory or PR noise around future exclusivity‑dependent revenues. Read More.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the transaction, the insider owned 128,779 shares of the company’s stock, valued at approximately $18,152,687.84. This trade represents a 2.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the transaction, the chief financial officer directly owned 176,191 shares of the company’s stock, valued at $24,835,883.36. The trade was a 1.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 178,640 shares of company stock worth $26,584,250 in the last 90 days. Insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.